Drug
Baxdrostat clinical trials
Also written CIN-107 and RO6836191,.
- studies test it
- 28
- open now
- 5
- in phase 3
- 9
- first study started
- 2013
Keep track of what changes. Save the baxdrostat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
28 studies that test it; most in 2024 (7)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 7 |
| 2025 | 4 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 7
- Phase 3
- 9
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 26 · Other 2
AstraZeneca (23) · CinCor Pharma, Inc. (2) · Hoffmann-La Roche (1) · Queen Mary University of London (1) · Subodh Verma (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses baxdrostat is read from its arms, and is right about nine times in ten.
Testing it · 28
- Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinRecruitingPhase 3AstraZenecaNCT06677060Written as Baxdrostat and dapagliflozin
- A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.RecruitingPhase 3AstraZenecaNCT07686120Written as baxdrostat 2mg
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureRecruitingPhase 3AstraZenecaNCT06742723Written as Baxdrostat/dapagliflozin
- Baxdrostat and Molecular Imaging of Adrenal Cytoreduction in Primary AldosteronismNot yet recruitingNot applicableQueen Mary University of LondonNCT07800858Written as baxdrostat
- Baxdrostat and Ventricular RemodelingNot yet recruitingPhase 3Subodh VermaNCT07655362Written as Baxdrostat
- Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.Active, not recruitingPhase 3AstraZenecaNCT07007793Written as Baxdrostat
- A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.Active, not recruitingPhase 2AstraZenecaNCT07222917Written as Baxdrostat/dapagliflozin
- A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant HypertensionCompletedPhase 3AstraZenecaNCT06168409Written as Baxdrostat
- A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypertensionCompletedPhase 3AstraZenecaNCT06034743Written as Baxdrostat
- A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.Active, not recruitingPhase 3AstraZenecaNCT06268873Written as Baxdrostat/dapagliflozin
- A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypertensionCompletedPhase 3AstraZenecaNCT06344104Written as Baxdrostat
- A Study of CIN-107 in Adults With Primary AldosteronismCompletedPhase 2AstraZenecaNCT04605549Written as CIN-107 2 mg dosing
- A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled HypertensionCompletedPhase 2AstraZenecaNCT06336356Written as Baxdrostat
- A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney DiseaseCompletedPhase 2AstraZenecaNCT05432167Written as CIN-107
- A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy ParticipantsCompletedPhase 1AstraZenecaNCT06194032Written as Baxdrostat
- A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing PotentialCompletedPhase 1AstraZenecaNCT06657105Written as Baxdrostat
- Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124CompletedPhase 2AstraZenecaNCT05459688Written as CIN-107
- A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination With Itraconazole in Healthy ParticipantsCompletedPhase 1AstraZenecaNCT06357520Written as Baxdrostat
- Phase 1 Study to Determine the Metabolism and Clearance of BaxdrostatCompletedPhase 1AstraZenecaNCT05961384Written as baxdrostat
- Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy SubjectsCompletedPhase 1AstraZenecaNCT05500820Written as CIN-107
Codes
What other systems call baxdrostat · ClinicalTrials.gg INT002198
- MeSH (NLM) C000732025baxdrostatOne source NLM
- UNII (FDA) NF3P9Z8J5YBAXDROSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q123485866baxdrostatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C184908BaxdrostatOne source FDA
- DrugBank DB19090One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000732025 | baxdrostat | One source NLM |
| UNII (FDA) | NF3P9Z8J5Y | BAXDROSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123485866 | baxdrostat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C184908 | Baxdrostat | One source FDA |
| DrugBank | DB19090 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.